AtriCure to Participate at the Oppenheimer 31st Annual Healthcare Conference

MASON, Ohio--(BUSINESS WIRE)-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that the company will be participating in the upcoming Oppenheimer 31st Annual Healthcare Conference.

AtriCure’s management is scheduled to present on Tuesday, March 16, 2021, at 1:10 p.m. Eastern Time. Interested parties may access a live and archived audio webcast of the presentation by visiting the “Investors” section of the company’s website at https://ir.atricure.com.

About AtriCure

AtriCure, Inc. provides innovative technologies for the treatment of Afib and related conditions. Afib affects more than 33 million people worldwide. Electrophysiologists and cardiothoracic surgeons around the globe use AtriCure technologies for the treatment of Afib and reduction of Afib related complications. AtriCure’s Isolator® Synergy™ Ablation System is the first and only medical device to receive FDA approval for the treatment of persistent Afib. AtriCure’s AtriClip® Left Atrial Appendage Exclusion System products are the most widely sold LAA management devices worldwide. For more information, visit AtriCure.com or follow us on Twitter @AtriCure.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210302006057/en/

Angie Wirick
AtriCure, Inc.
Chief Financial Officer
(513) 755-5334
[email protected]

Lynn Pieper Lewis
Gilmartin Group
Investor Relations
(415) 937-5402
[email protected]

Source: AtriCure, Inc.

You May Also Be Interested In

• AtriCure (ATRC) Announces Launch of the cryoSPHERE+
• Sharing Experiences for Mutual Success: Heilongjiang Ice and Snow Tourism link with Northern Europe as a silver silk ribbon
• DHGATE Group wins "Best B2B Cross-Border e-commerce Marketplace Company China 2024" at the Global Business & Finance Magazine